Enquirer Consulting Group

Reachable Buyer Map

Prepared for Aymeric de Gantès, EnginZyme · August 2026
Here is the map. You sell a manufacturing route rather than a product, which means every deal has two buyers who answer different questions: the chemistry lead who decides whether the enzymatic route works, and the plant or commercial owner who decides whether it is worth changing a process that already runs. This covers where both sit across the industries you already name, the segments they cluster in, and roughly how many companies stand behind each. It describes the market rather than your business, and there is nothing to buy at the end of it.
Flavor, fragrance and aroma chemical producers
The market that moves first, because the switch from an extracted or petro-route ingredient to an enzymatic one is a story the end brand can tell as well as a cost the plant can defend. Concentrated, well mapped, and small enough that the same twenty names appear in every conversation.
Who signs: VP of research and development, head of process chemistry, chief technology officer, and the sourcing lead who owns naturals.
450 to 650
producers across Europe and North America
Cosmetic and personal care ingredient makers
The segment you already talk about publicly, and the one where the register understates the market. Brand owners who commission an ingredient but outsource the chemistry do not file as chemical manufacturers, so they surface under wholesale and consumer goods codes instead. The layer above the countable one is materially larger.
Who signs: head of ingredient research, VP of technology, the sustainability lead, and the category manager who owns actives.
800 to 1,100
registered ingredient producers in Europe and North America; the brand owner layer above is not separately enumerated
Edible oil and fat processors
Small by count and unusually consequential, because a single processing group runs several plants and one qualified route travels across all of them. Long technical evaluation, then volume. These are the buyers for whom an enzymatic route is an engineering decision rather than a marketing one.
Who signs: plant technology director, head of process engineering, VP of operations, and the procurement director on the commercial side.
250 to 400
processing groups across Europe and North America; site count is several times higher
Specialty and fine chemical manufacturers
The largest group on this page and the least worked, because it is too big to reach through partnerships and too varied to reach through one message. Inside it sit the contract producers who make other companies' molecules, which makes them a route to several buyers at once.
Who signs: chief technology officer, head of process development, site director, and the business unit head who owns the margin.
3,000 to 4,000
registered manufacturers in Europe alone; North America adds a comparable layer
Pharmaceutical API makers and contract manufacturers
Slowest to qualify and hardest to displace once qualified, which cuts both ways. Biocatalysis is already accepted vocabulary here, so the conversation starts further along than it does elsewhere. Regulated change control is the gate, not the science.
Who signs: head of chemical development, VP of manufacturing science and technology, external manufacturing lead, and the site quality head as a blocker.
900 to 1,300
API and contract manufacturing sites across Europe and North America
Industrial biotech and precision fermentation companies
Peers rather than customers in some cases, and buyers in others, because a cell-free step often sits upstream or downstream of a fermentation one. Fast to decide, technically fluent, and rarely reached by anyone selling into established chemical plants. Worth being straight: this group is not enumerated in any public register.
Who signs: founder or chief technology officer, head of process development, and the investor-facing operator on partnership decisions.
No public register
identified one at a time by what they publish and where they are funded

Where the openings are

1
Nothing public records who is choosing a route this quarter. Process technology is bought at a moment: a new plant, a capacity expansion, a reformulation forced by a customer, a sustainability commitment with a date on it, a new head of process development in the seat. Those moments are visible from outside if someone watches several thousand named companies for them, and invisible if you are waiting to be introduced.
2
Two people have to say yes and they answer different questions. The chemistry buyer decides whether the route works. The plant or commercial owner decides whether it is worth changing a line that already runs and already passes audit. Partnership and conference routes reach the first one well and the second one almost never, which is where evaluations stall.
3
The developed-process route selects for who already knows you. The segments above come to several thousand companies before you count the sites behind them. A partner introduction reaches whichever slice touches that partner. The rest are not unqualified, they simply have not heard the argument yet, and reaching them by name is mechanical work rather than relationship work.
Built from public market data covering registered manufacturers in Europe and North America, counts banded deliberately. Segment codes are self-reported by the companies themselves, so the edges between specialty chemicals, ingredients and pharmaceutical production blur. Very small and owner-only producers are not consistently published. Process technology decisions are not recorded in any public source anywhere, so these figures count companies rather than live projects.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com